By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Angion Biomedica Corp. 

1050 Stewart Avenue

Garden City  New York  11530  U.S.A.
Phone: 516-869-6400 Fax: 516-869-1359



Company News
Angion Biomedica Corp. Exclusively In-Licenses Aldosterone Synthase Inhibitors From ElexoPharm GmbH Complementing Its Ongoing Program In Chronic Kidney Disease 6/22/2017 6:35:36 AM
Angion Biomedica Corp.'s Phase 2 “GUARD” Clinical Trial Of BB3 In Acute Kidney Injury (AKI) Underway; Complements Ongoing Phase 3 Study In Renal Transplant Recipients With Delayed Graft Function (DGF) 1/31/2017 10:13:11 AM
Angion Biomedica Corp. To Present Clinical And Preclinical Data At The Upcoming American Society of Nephrology Conference In San Diego 11/2/2015 9:06:14 AM
Angion Biomedica Corp. To Commence Phase 2 Clinical Trial Of BB3 In Acute Kidney Injury 6/9/2015 10:52:53 AM
Angion Biomedica Corp. Advances BB3 Into Pivotal Phase 3 Clinical Trial In Renal Transplant Patients With Delayed Graft Function 5/14/2015 10:47:49 AM
Organ Recovery Biotech Angion Biomedica Corp. Files For A $35 Million IPO 4/15/2014 8:31:03 AM
First Patient Treated in Angion Biomedica Corp.'s Phase II BB3 Heart Attack Clinical Trial 7/18/2012 8:51:08 AM
Angion Biomedica Corp. Receives Fast Track and Orphan Drug Product Designations from FDA for its Lead Therapeutic, BB3 7/6/2010 8:15:08 AM
Angion Biomedica Corp. Has Signed Licensing Option With Memorial Sloan-Kettering Cancer Center For Novel Vaccine Platform 1/8/2009 8:39:18 AM